A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

Inclusion Criteria:

1. Willing and able to participate and comply with all trial requirements and able toprovide signed and dated informed consent prior to initiation of any trialprocedures;

2. Male or female 18-75 years;

3. Meet diagnostic criteria for a diabetic ulcer with the presence of at least onetarget ulcer that meets the characteristics:

• Located on dorsal or plantar surface of foot or below the knee.

• Wagner grade 2, ulcerated lesion at or below the knee, without systemicinfection.

• The target ulcer should be the largest, and all each individual ulcers sizeshould be less than 25cm2. All ulcers will be treated the same as the targetulcer.

• Target ulcers persisted for at least 12 weeks prior to enrollment and have beenon standard of care for at least 4 weeks prior to enrollment.

• There is a minimum 3cm margin between the qualifying Target Ulcer and any otherulcers on the specified foot (post-debridement).

Exclusion Criteria:

1. Allergy to the main components or excipients of MDI-1228_mesylate gel, allergy toJAK inhibitors (tofacitib, baricitinib, ruxolitinib), or individuals with allergicconstitution.

2. Skin ulcers or chronic wounds caused by electroshock, chemicals, radioactivematerial etc.

3. The target ulcer has reduced in size by ≥30% in the last 4 weeks under standardtreatment.

4. Those with cancerous ulcers or connective tissue diseases including lupuserythematosus, rheumatoid arthritis, scleroderma, etc.